Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2015

01.06.2015 | review

Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas

verfasst von: MD, PhD Asst. Prof. Theodoros P. Vassilakopoulos, MD Vassilios Prassopoulos, MD, FENMB Phoivi Rondogianni, MD, PhD Assoc. Prof. Sofia Chatziioannou, MD, PhD Prof. Kostas Konstantopoulos, MD, PhD Asst. Prof. Maria K. Angelopoulou

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Positron emission tomography with integrated computed tomography (PET/CT) is increasingly used for the initial staging, final or even interim (mid-treatment) response assessment in malignant lymphomas. Extensive clinical experience has been gained with Hodgkin lymphoma (HL) and aggressive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL) and other subtypes, which are the subject of the present review. The use of PET/CT is now considered mandatory for baseline staging in these entities, providing more accurate information and obviating the need of bone marrow biopsy (BMB) at least in HL. PET/CT has been the long-standing “gold standard” for final response assessment. Furthermore, early interim PET evaluation provides valuable prognostic information in HL and DLBCL. In HL, it appears that treatment intensification with Bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP)-escalated can improve disease control in patients with persistent PET positivity after two cycles of ABVD. However, there is no randomized evidence of survival benefit as yet. In contrast, regimens effective in overcoming the adverse impact of persistent PET positivity have not been yet described in DLBCL. The 2014 recommendations suggest the use of PET/CT for baseline staging and final response assessment in all [18F]fluorodeoxyglucose (FDG)-avid lymphoma subtypes, including the above named ones. The use of interim evaluation is not considered fully documented yet. The exact role of PET/CT in guiding treatment decisions has to be defined by ongoing and future randomized trials and evidence-based approaches are expected to become available in the near future.
Literatur
1.
Zurück zum Zitat Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86. PubMedCrossRef Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86. PubMedCrossRef
2.
Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA, et al. Recommendations for the initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67. PubMedCrossRef Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA, et al. Recommendations for the initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67. PubMedCrossRef
3.
Zurück zum Zitat Barrington SF, Mikhaeel GN, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58. Barrington SF, Mikhaeel GN, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.
4.
Zurück zum Zitat Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology 2012, Am Soc Hematol Educ Programm Book. 2012. pp 322–327.doi: 10.1182/asheducation-2012.1.322. Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology 2012, Am Soc Hematol Educ Programm Book. 2012. pp 322–327.doi: 10.1182/asheducation-2012.1.322.
5.
Zurück zum Zitat Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, et al. Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol. 2013;31(S1):137. (abstr 123). Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, et al. Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol. 2013;31(S1):137. (abstr 123).
6.
Zurück zum Zitat Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91. PubMedCrossRef Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91. PubMedCrossRef
7.
Zurück zum Zitat Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16. PubMedCrossRef Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16. PubMedCrossRef
8.
Zurück zum Zitat Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36:745–50. PubMedCrossRef Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36:745–50. PubMedCrossRef
9.
Zurück zum Zitat Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17:239–49. PubMedCentralPubMedCrossRef Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17:239–49. PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, et al. [ 18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32:1769–75. PubMedCrossRef Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, et al. [ 18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32:1769–75. PubMedCrossRef
11.
Zurück zum Zitat El-Galaly TC, d’ Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naïve patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508–14. PubMedCrossRef El-Galaly TC, d’ Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naïve patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508–14. PubMedCrossRef
12.
Zurück zum Zitat Vassilakopoulos TP, Angelopoulou MK, Constantinou N, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood. 2005;105:1875–80. PubMedCrossRef Vassilakopoulos TP, Angelopoulou MK, Constantinou N, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood. 2005;105:1875–80. PubMedCrossRef
13.
Zurück zum Zitat Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol. 2014;25:921–7. PubMedCrossRef Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol. 2014;25:921–7. PubMedCrossRef
14.
Zurück zum Zitat Vassilakopoulos TP, Rondogianni P, Prassopoulos V, Chatziioannou S, Moschogiannis M, Poziopoulos C, et al. Comparative assessment of bone marrow involvement (BMI) by bone marrow biopsy (BMB) or positron emission tomography/computed tomography (PET/CT) in Hodgkin lymphoma (HL). Haematologica. 2014;99(Suppl 1):401 (abstr. 1050). Vassilakopoulos TP, Rondogianni P, Prassopoulos V, Chatziioannou S, Moschogiannis M, Poziopoulos C, et al. Comparative assessment of bone marrow involvement (BMI) by bone marrow biopsy (BMB) or positron emission tomography/computed tomography (PET/CT) in Hodgkin lymphoma (HL). Haematologica. 2014;99(Suppl 1):401 (abstr. 1050).
15.
Zurück zum Zitat Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452–7. PubMedCrossRef Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452–7. PubMedCrossRef
16.
Zurück zum Zitat Adams HJA, Kwee TC, Finjnheer R, Dubois SV, Nievelstein AJR, de Klerk JMH. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol. 2014;89:726–31. PubMedCrossRef Adams HJA, Kwee TC, Finjnheer R, Dubois SV, Nievelstein AJR, de Klerk JMH. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol. 2014;89:726–31. PubMedCrossRef
17.
Zurück zum Zitat Hong J, Lee Y, Park Y, et al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 2012;91:687–95. PubMedCrossRef Hong J, Lee Y, Park Y, et al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 2012;91:687–95. PubMedCrossRef
18.
Zurück zum Zitat Cerci JJ, Gyorke T, Fanti S, Paez D, Meneghetti JC, Redondo F, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1591–7. PubMedCrossRef Cerci JJ, Gyorke T, Fanti S, Paez D, Meneghetti JC, Redondo F, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1591–7. PubMedCrossRef
19.
Zurück zum Zitat Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54:1244–50. PubMedCrossRef Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54:1244–50. PubMedCrossRef
20.
Zurück zum Zitat Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61–7. PubMedCrossRef Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61–7. PubMedCrossRef
21.
Zurück zum Zitat Adams HJA, Kwee TC. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma. J Clin Oncol. 2015. doi:10.1200/JCO.2014.58.7360. (Epub 17 Feb 2015). Adams HJA, Kwee TC. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma. J Clin Oncol. 2015. doi:10.1200/JCO.2014.58.7360. (Epub 17 Feb 2015).
22.
Zurück zum Zitat Meignan M, Itti E, Gallamini A, Younes A. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-014-2973-6. (Epub 09 Jan 2015). Meignan M, Itti E, Gallamini A, Younes A. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-014-2973-6. (Epub 09 Jan 2015).
23.
Zurück zum Zitat Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumor volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43. PubMedCrossRef Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumor volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43. PubMedCrossRef
24.
Zurück zum Zitat Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci. 2013;104:1656–61. PubMedCrossRef Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci. 2013;104:1656–61. PubMedCrossRef
25.
Zurück zum Zitat Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumor volume is an independent predictor of outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22. PubMedCrossRef Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumor volume is an independent predictor of outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22. PubMedCrossRef
26.
Zurück zum Zitat Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703. PubMedCentralPubMedCrossRef Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703. PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195–202. PubMedCrossRef Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195–202. PubMedCrossRef
28.
Zurück zum Zitat Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8. PubMedCrossRef Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8. PubMedCrossRef
29.
Zurück zum Zitat Vassilakopoulos TP, Pangalis GA, Boutsikas G, et al. Prognostic factors in patients with Hodgkin lymphoma (HL) and a negative PET/CT after ABVD chemotherapy: potential applications for the design of follow-up strategies. Haematologica. 2012;97(Suppl 1):87. (abstr. 218). Vassilakopoulos TP, Pangalis GA, Boutsikas G, et al. Prognostic factors in patients with Hodgkin lymphoma (HL) and a negative PET/CT after ABVD chemotherapy: potential applications for the design of follow-up strategies. Haematologica. 2012;97(Suppl 1):87. (abstr. 218).
30.
Zurück zum Zitat Radford J, Illidge T, Counsell L, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–607. PubMedCrossRef Radford J, Illidge T, Counsell L, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–607. PubMedCrossRef
31.
Zurück zum Zitat Hartridge-Lambert SK, Schoder H, Lim RC, Maragulia JC, Portlock CS. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma. Cancer. 2013;119:1203–9. PubMedCrossRef Hartridge-Lambert SK, Schoder H, Lim RC, Maragulia JC, Portlock CS. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma. Cancer. 2013;119:1203–9. PubMedCrossRef
32.
Zurück zum Zitat Sher DJ, Mauch PM, van den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved field radiotherapy. Ann Oncol. 2009;20:1848–53. PubMedCrossRef Sher DJ, Mauch PM, van den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved field radiotherapy. Ann Oncol. 2009;20:1848–53. PubMedCrossRef
33.
Zurück zum Zitat Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9. PubMedCrossRef Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9. PubMedCrossRef
34.
Zurück zum Zitat Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited stage Hodgkin’s lymphoma. Ann Oncol. 2011;22:910–5. PubMedCrossRef Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited stage Hodgkin’s lymphoma. Ann Oncol. 2011;22:910–5. PubMedCrossRef
35.
Zurück zum Zitat Vassilakopoulos TP, Rontogianni P, Pangalis GA, et al. Outcome and prognostic factors in patients with Hodgkin lymphoma (HL) who remain PET/CT-positive after ABVD combination chemotherapy: potential applications for the design of subsequent treatment. Haematologica. 2012;97(Suppl 1):562 (abstr. 1404). Vassilakopoulos TP, Rontogianni P, Pangalis GA, et al. Outcome and prognostic factors in patients with Hodgkin lymphoma (HL) who remain PET/CT-positive after ABVD combination chemotherapy: potential applications for the design of subsequent treatment. Haematologica. 2012;97(Suppl 1):562 (abstr. 1404).
36.
Zurück zum Zitat Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol. 2014;32:1776–81. PubMedCrossRef Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol. 2014;32:1776–81. PubMedCrossRef
37.
Zurück zum Zitat Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48:1721–7. PubMedCrossRef Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48:1721–7. PubMedCrossRef
38.
Zurück zum Zitat Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–94. PubMedCrossRef Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–94. PubMedCrossRef
39.
Zurück zum Zitat Illidge T. Radiotherapy in early stage Hodgkin lymphoma. Hematol Oncol. 2013;31(Suppl 1):92–5. PubMedCrossRef Illidge T. Radiotherapy in early stage Hodgkin lymphoma. Hematol Oncol. 2013;31(Suppl 1):92–5. PubMedCrossRef
40.
Zurück zum Zitat Vassilakopoulos TP, Pangalis GA, Chatziioannou S, et al. PET/CT in patients with primary mediastinal large B-cell lymphoma responding to Rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia. 2015. doi: 10.1038/leu.2015.120. Vassilakopoulos TP, Pangalis GA, Chatziioannou S, et al. PET/CT in patients with primary mediastinal large B-cell lymphoma responding to Rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia. 2015. doi: 10.1038/leu.2015.120.
41.
Zurück zum Zitat Martelli M, Ceriani L, Zucca E, et al. [ 18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32:1769–75. PubMedCrossRef Martelli M, Ceriani L, Zucca E, et al. [ 18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32:1769–75. PubMedCrossRef
42.
Zurück zum Zitat Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–16. PubMedCrossRef Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–16. PubMedCrossRef
43.
Zurück zum Zitat Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys. 2013;87:311–6. PubMedCrossRef Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys. 2013;87:311–6. PubMedCrossRef
44.
Zurück zum Zitat Vassilakopoulos TP, Pangalis GA, Polliack A. A “PET” topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. Leuk Lymphoma. 2015;56:3–5. PubMedCrossRef Vassilakopoulos TP, Pangalis GA, Polliack A. A “PET” topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. Leuk Lymphoma. 2015;56:3–5. PubMedCrossRef
45.
Zurück zum Zitat Martelli M, Zucca E, Gospodarowicz M, Johnson PWM, Ricardi U. A randomized, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL): the IELSG-37 study. Hematol Oncol. 2013;31(S1):140. Martelli M, Zucca E, Gospodarowicz M, Johnson PWM, Ricardi U. A randomized, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL): the IELSG-37 study. Hematol Oncol. 2013;31(S1):140.
46.
Zurück zum Zitat Dupuis J, Itti E, Rahmouni A, Hemery F, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503–7. PubMedCrossRef Dupuis J, Itti E, Rahmouni A, Hemery F, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503–7. PubMedCrossRef
47.
Zurück zum Zitat Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2631–8. PubMedCrossRef Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2631–8. PubMedCrossRef
48.
Zurück zum Zitat Vassilakopoulos TP, Kanellopoulos A, Papageorgiou S, Pangalis GA, Anastasopoulou A, Moschogianni M, et al. Clinical implications and prognostic significance of positron emission tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) after R-CHOP chemoimmunotherapy. Haematologica. 2014;99(Suppl 1): 702. (abstr. 1831). Vassilakopoulos TP, Kanellopoulos A, Papageorgiou S, Pangalis GA, Anastasopoulou A, Moschogianni M, et al. Clinical implications and prognostic significance of positron emission tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) after R-CHOP chemoimmunotherapy. Haematologica. 2014;99(Suppl 1): 702. (abstr. 1831).
49.
Zurück zum Zitat Thomas A, Gingrich RD, Smith BJ, et al. 18-fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of “indeterminate” reports. Leuk lymphoma. 2010;51:439–46. PubMedCentralPubMedCrossRef Thomas A, Gingrich RD, Smith BJ, et al. 18-fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of “indeterminate” reports. Leuk lymphoma. 2010;51:439–46. PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, et al. Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol. 2013;31(S1):137. (abstr. 123). Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, et al. Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol. 2013;31(S1):137. (abstr. 123).
51.
Zurück zum Zitat Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066–73. PubMedCrossRef Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066–73. PubMedCrossRef
52.
Zurück zum Zitat Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9. PubMedCrossRef Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9. PubMedCrossRef
53.
Zurück zum Zitat Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52. PubMedCrossRef Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52. PubMedCrossRef
54.
Zurück zum Zitat Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG-PET interpretation in diffuse large B-cell Lymphoma: importance of the reference background. J Nucl Med. 2010;51:1857–62. PubMedCrossRef Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG-PET interpretation in diffuse large B-cell Lymphoma: importance of the reference background. J Nucl Med. 2010;51:1857–62. PubMedCrossRef
55.
Zurück zum Zitat Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903. PubMedCentralPubMedCrossRef Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903. PubMedCentralPubMedCrossRef
56.
Zurück zum Zitat Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol. 2014;93:1297–304. PubMedCrossRef Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol. 2014;93:1297–304. PubMedCrossRef
57.
Zurück zum Zitat Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglou L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13. PubMedCentralPubMedCrossRef Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglou L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13. PubMedCentralPubMedCrossRef
58.
Zurück zum Zitat Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90. PubMedCrossRef Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90. PubMedCrossRef
59.
Zurück zum Zitat Kostakoglu L, Schoder H, Johnson JL, et al. Interim FDG PET imaging in stage I/II non bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Leuk Lymphoma. 2012;53:2143–50. PubMedCrossRef Kostakoglu L, Schoder H, Johnson JL, et al. Interim FDG PET imaging in stage I/II non bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Leuk Lymphoma. 2012;53:2143–50. PubMedCrossRef
60.
Zurück zum Zitat Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014;165:112–6. PubMedCrossRef Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014;165:112–6. PubMedCrossRef
61.
Zurück zum Zitat Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, et al. The prognostic value of positron emission tomography performed after two courses (interim-pet) of standard therapy on treatment outcome in early stage Hodgkin lymphoma. A multicentric study by the Fondazione Italiana Linfomi (FIL). Am J Hematol. 2015. doi:10.1002/ajh.23994. Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, et al. The prognostic value of positron emission tomography performed after two courses (interim-pet) of standard therapy on treatment outcome in early stage Hodgkin lymphoma. A multicentric study by the Fondazione Italiana Linfomi (FIL). Am J Hematol. 2015. doi:10.1002/ajh.23994.
62.
Zurück zum Zitat Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011;152:551–60. PubMedCrossRef Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011;152:551–60. PubMedCrossRef
63.
Zurück zum Zitat Press O, Li H, Schoder H, LeBlanc M, Rimsza L, Friedberg JW, et al. Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US Intergroup S0816. Haematologica. 2013;98(S2):36. (abstr. T108). Press O, Li H, Schoder H, LeBlanc M, Rimsza L, Friedberg JW, et al. Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US Intergroup S0816. Haematologica. 2013;98(S2):36. (abstr. T108).
64.
Zurück zum Zitat Johnson P, Federico M, Fossa A, O’ Doherty M, Roberts T, Stevens L, et al. Responses and chemotherapy dose adjustment determined by PET-CT imaging: first results from the international response adapted therapy in advanced Hodgkin lymphoma (RATHL) study. Hematol Oncol. 2013;31(S1):138. (abstr. 126). CrossRef Johnson P, Federico M, Fossa A, O’ Doherty M, Roberts T, Stevens L, et al. Responses and chemotherapy dose adjustment determined by PET-CT imaging: first results from the international response adapted therapy in advanced Hodgkin lymphoma (RATHL) study. Hematol Oncol. 2013;31(S1):138. (abstr. 126). CrossRef
65.
Zurück zum Zitat Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced stage Hodgkin’s lymphoma has a high negative predictive value. Ann Oncol. 2009;20:1270–4. PubMedCrossRef Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced stage Hodgkin’s lymphoma has a high negative predictive value. Ann Oncol. 2009;20:1270–4. PubMedCrossRef
66.
Zurück zum Zitat Borchmann P, Haverkamp H, Lohri A, Kreissl S, Greil R, Markova J, et al. Addition of rituximab to BEACOPP escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study. Blood. 2014;124:Abstract 500. (ASH Annual Meeting Abstracts). Borchmann P, Haverkamp H, Lohri A, Kreissl S, Greil R, Markova J, et al. Addition of rituximab to BEACOPP escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study. Blood. 2014;124:Abstract 500. (ASH Annual Meeting Abstracts).
67.
Zurück zum Zitat Vassilakopoulos TP, Angelopoulou MK, Rondogianni P, et al. Interim PET-Scan for early response assessment and potential modification of treatment plan after 2 ABVD cycles in advanced stage Hodgkin Lymphoma (HL). Haematologica. 2011;96(Suppl 2):abstr 322. Vassilakopoulos TP, Angelopoulou MK, Rondogianni P, et al. Interim PET-Scan for early response assessment and potential modification of treatment plan after 2 ABVD cycles in advanced stage Hodgkin Lymphoma (HL). Haematologica. 2011;96(Suppl 2):abstr 322.
68.
Zurück zum Zitat Cimino G, Zaucha JM, Cirillo S, Saviolo C, Hutchings M, El-Galaly TC, et al. The complementary prognostic role of baseline and interim PET in predicting treatment outcome in advanced-stage Hodgkin lymphoma. Blood. 2014;124:Abstract 4405. (ASH Annual Meeting Abstracts). Cimino G, Zaucha JM, Cirillo S, Saviolo C, Hutchings M, El-Galaly TC, et al. The complementary prognostic role of baseline and interim PET in predicting treatment outcome in advanced-stage Hodgkin lymphoma. Blood. 2014;124:Abstract 4405. (ASH Annual Meeting Abstracts).
69.
Zurück zum Zitat Agostinelli C. A clinical-pathological algorithm based on the combination of interim PET with biological markers in classical Hodgkin lymphoma. Presented at the Fifth International Workshop on PET in Lymphoma, Menton, 19–20 September 2014. http://​eitti.​free.​fr. Agostinelli C. A clinical-pathological algorithm based on the combination of interim PET with biological markers in classical Hodgkin lymphoma. Presented at the Fifth International Workshop on PET in Lymphoma, Menton, 19–20 September 2014. http://​eitti.​free.​fr.
70.
Zurück zum Zitat Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;20:4548–54. CrossRef Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;20:4548–54. CrossRef
71.
Zurück zum Zitat Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9. PubMedCrossRef Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9. PubMedCrossRef
72.
Zurück zum Zitat von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30:907–13. CrossRef von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30:907–13. CrossRef
73.
Zurück zum Zitat Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55:569–73. PubMedCrossRef Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55:569–73. PubMedCrossRef
74.
Zurück zum Zitat Moskowitz C, Hamlin PA, Maragulia J, Meikle J, Zelenetz AD. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma. Blood. 2010;116:abstr 420. Moskowitz C, Hamlin PA, Maragulia J, Meikle J, Zelenetz AD. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma. Blood. 2010;116:abstr 420.
75.
Zurück zum Zitat Horning SJ, Juweid ME, Schoeder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775–7. PubMedCentralPubMedCrossRef Horning SJ, Juweid ME, Schoeder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775–7. PubMedCentralPubMedCrossRef
76.
Zurück zum Zitat Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53:1876–81. PubMedCrossRef Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53:1876–81. PubMedCrossRef
77.
Zurück zum Zitat Carr R, Fanti S, Paez D, Cerci J, Gyorke T, Redondo F, et al. Prospective international cohort study demonstrates inability if interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1936–44. PubMedCrossRef Carr R, Fanti S, Paez D, Cerci J, Gyorke T, Redondo F, et al. Prospective international cohort study demonstrates inability if interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1936–44. PubMedCrossRef
78.
Zurück zum Zitat Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Verra P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20. PubMedCrossRef Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Verra P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20. PubMedCrossRef
79.
Zurück zum Zitat Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43. PubMedCrossRef Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43. PubMedCrossRef
80.
Zurück zum Zitat Dührsen U, Hüttmann A, Jöckel KH, Müller S. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas–the PETAL trial. Leuk Lymphoma. 2009;50:1757–60. PubMedCrossRef Dührsen U, Hüttmann A, Jöckel KH, Müller S. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas–the PETAL trial. Leuk Lymphoma. 2009;50:1757–60. PubMedCrossRef
81.
Zurück zum Zitat Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke J, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood. 2014;124:Abstract 391. (ASH Annual Meeting Abstracts). Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke J, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood. 2014;124:Abstract 391. (ASH Annual Meeting Abstracts).
82.
Zurück zum Zitat Swinnen LJ, Li H, Quon A, Gascoyne RD, Ranheim EA, Hong F, et al. Response-adapted therapy and predictive value of mid-treatment PET scanning for diffuse large B-cell lymphoma. ECOG study E3404. Hematol Oncol. 2013;31(S1):138 (abstr. 126). (101 (abstr. 016)). Swinnen LJ, Li H, Quon A, Gascoyne RD, Ranheim EA, Hong F, et al. Response-adapted therapy and predictive value of mid-treatment PET scanning for diffuse large B-cell lymphoma. ECOG study E3404. Hematol Oncol. 2013;31(S1):138 (abstr. 126). (101 (abstr. 016)).
83.
Zurück zum Zitat Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst Rev. 2015;1:CD010533. doi:10.1002/14651858.CD010533.pub2. PubMed Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst Rev. 2015;1:CD010533. doi:10.1002/14651858.CD010533.pub2. PubMed
Metadaten
Titel
Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas
verfasst von
MD, PhD Asst. Prof. Theodoros P. Vassilakopoulos
MD Vassilios Prassopoulos
MD, FENMB Phoivi Rondogianni
MD, PhD Assoc. Prof. Sofia Chatziioannou
MD, PhD Prof. Kostas Konstantopoulos
MD, PhD Asst. Prof. Maria K. Angelopoulou
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0215-7